Abstract
The outcome of patients with aggressive refractory diffuse large B-cell lymphoma (DLCL) is generally poor. A 43-year-old female with DLCL, who relapsed after first line chemotherapy (CHOP-cyclophosphamide, doxorubicin, vincristine, and prednisone) and progressed despite salvage chemotherapy (EPOCH-etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin), was treated effectively with 8 cycles of Rituximab. She is without evidence of disease with a follow-up of 32 months. We report this case to bring to attention the possibility of sustained durable remission with single agent Rituximab in refractory DLCL.
Original language | English (US) |
---|---|
Pages (from-to) | 2235-2236 |
Number of pages | 2 |
Journal | Leukemia and Lymphoma |
Volume | 43 |
Issue number | 11 |
DOIs | |
State | Published - Nov 1 2002 |
Externally published | Yes |
Keywords
- Diffuse large B-cell lymphoma
- Lymphoma
- Rituxan
- Rituximab
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research